CatalYm is a biotechnology company developing innovative immunotherapies for cancer patients.
CatalYm has raised $150.0M in total funding. The most recent round was Series D. The last funding was announced in July 2024.
CatalYm's investors include Omega Funds, Canaan Partners, Forbion Capital Partners, Brandon Capital, BioGeneration Ventures.
CatalYm is headquartered in Planegg, Germany.
CatalYm is a biotechnology company developing innovative immunotherapies for cancer patients.
CatalYm is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"CatalYm — Funding & Investors." VCBacked, July 16, 2024, https://www.vcbacked.co/company/catalym. Accessed August 15, 2026.
VCBacked. (2024). CatalYm — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/catalym
{{cite web |title=CatalYm — Funding & Investors |url=https://www.vcbacked.co/company/catalym |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated